Concurrent Session 4C: Microbes and Cancer: The Microbiome’s Role in Carcinogenesis; CME (AMA PRA Category 1 CreditsTM) 1.5; Attendance CEU 1.5

Thursday, September 13
1:45 PM - 3:15 PM
Location: Mayo Civic Center Rooms 110-111

Our body is home to trillions of microorganisms which play an important role in our health. The advent of next generation sequencing and rapid decline in cost has enabled us to study the relevance of these microorganisms in human health without the need to grow them in the laboratory. In this session, we will focus on specific bacteria in our gut and other locations that can cause cancer, predict our risk of cancer and determine our response to cancer therapy.

Learning Objectives:

Moderator :
Heidi Nelson, MD

Professor of Surgery, College of Medicine and Science
Mayo Clinic
Rochester

Presentation(s):

Send Email for Heidi Nelson

Concurrent Speaker :
Arielle Elkrief, MD

Resident
Medical Oncology
McGill University / Centre de recherche de l'Université de Montreal (CRCHUM)

Arielle Elkrief, MD received her MD from the University of Sherbrooke in 2015 and is currently completing her residency training in Medical Oncology at McGill University. She joined Dr. Bertrand Routy's laboratory at the University of Montreal Reseach Center (CRCHUM) to work on the gut microbiome. Dr. Elkrief's research focuses on the deleterious impact of antibiotics on patients receiving cancer therapies including immune checkpoint inhibitors (ICI). Her objective is to demonstrate that the gut microbiota composition has a major impact on ICI efficacy in various cancers.

Presentation(s):

Send Email for Arielle Elkrief

Concurrent Speaker :
Christian Jobin, PhD

Professor
Medicine
University of Florida

Christian Jobin, PhD is the Gatorade Trust Professor of Medicine at the University of Florida Gainesville. He received his PhD in Immunology/Microbiology from Université Laval (Quebec, Canada) in 1994. He did a post-doctoral fellowship at the University of North Carolina Chapel Hill working on bacteria host interaction in the intestine. Dr. Jobin’s research focuses on establishing mechanisms controlling host-bacteria interaction in the intestine. His laboratory is especially interested in the functional impact of bacteria in inflammation and carcinogenesis. Using genetically engineered mice and zebrafish, germ-free and gnotobiotic technology in combinat ion with microbial genomics, his lab studies the role of bacteria in cancer. He has published over 150 scientific papers (Science, Nature, Nat. Comm., Nat. Micro., Immunity, J. Exp. Med., Gastroenterology) and presented his work at various national and international scientific meetings (>150 conferences). His research, supported by the National Institute of Health has led to numerous awards and honours (Mucosal Immunology Society Award, American Gastroenterological Association Fiterman Young Investigator Basic Research Award, UF Senior Faculty Excellence in Research Award). Dr. Jobin has served on several study sections including American Cancer Society, CCFA Fellowship and Career Awards, NIH tumor microenvironment and he is currently serving on the Gastrointestinal Mucosal Pathobiology study section (GMPB-permanent member).

Presentation(s):

Send Email for Christian Jobin

Concurrent Speaker :
Marina Walther-Antonio, PhD

Assistant Professor of Surgery, College of Medicine and Science
Center for Individualized Medicine
Mayo Clinic
Rochester, Minnesota

Marina Walther-Antonio, PhD is an Associate Consultant in the Department of Surgery and an Assistant Professor in the Microbiome Program at Mayo Clinic. She leads an interdisciplinary research program that studies the role of the human microbiome in women's health, and in gynecologic cancers in particular. In order to achieve this, Dr. Walther-Antonio and her research team have characterized the female reproductive tract microbiome in benign gynecologic conditions, cancer precursors, and endometrial and ovarian cancer manifestation. Their efforts have resulted in the identification of microbiota markers for endometrial cancer and in the development of translational approaches towards early detection and prevention of the disease. The ultimate goal is to pinpoint intervention opportunities that are amenable to modification of disease risk or can diminish the use of aggressive therapeutic options. Dr. Walther-Antonio’s ovarian cancer research is concentrated on the search for an early detection microbiome biomarker and mechanistic role in response to therapy involving monitoring during a clinical trial and patient derived xenograft mouse model. Because mechanistic microbiome studies benefit from complex host/microbe interrogation with a cellular level of resolution, the research team is also focused on the development and application of single-cell microfluidic technologies, such as Optofluidics and Digital Microfluidics.

Presentation(s):

Send Email for Marina Walther-Antonio


Assets

Concurrent Session 4C: Microbes and Cancer: The Microbiome’s Role in Carcinogenesis; CME (AMA PRA Category 1 CreditsTM) 1.5; Attendance CEU 1.5

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Concurrent Session 4C: Microbes and Cancer: The Microbiome’s Role in Carcinogenesis; CME (AMA PRA Category 1 CreditsTM) 1.5; Attendance CEU 1.5